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The Epstein-Barr virus (EBV) BZLF1 gene product is thought to mediate the disruption of latent EBV
infection. We have examined the regulatory effects of BZLF1 by studying its transactivating effects on seven
different EBV promoters. We find that whereas the BZLF1 gene product increases the activity of the two early
promoters, BMLF1 and BMRF1, it decreases the activity of three latent promoters (the BamHI-C and
BamHI-W Epstein-Barr nuclear antigen promoters and the latent membrane protein promoter). The
BZLFl-induced changes in promoter-directed chloramphenicol acetyltransferase activity occur in EBV-
negative as well as EBV-positive cell lines and are accompanied by a similar change in chloramphenicol
acetyltransferase mRNA. Deletion analysis of the BamHI Z fragment indicates that a portion of the
amino-terminal half of the BZLF1 gene product (amino acids 24 to 86) is not essential for positive
transactivating effects but is required for down-regulating effects. Thus, different domains of the same EBV
immediate-early gene product can either increase the function of EBV promoters active in productive infection
or decrease the function of key promoters active in latent infection.
Epstein-Barr virus (EBV) infection of lymphoid cells is
largely latent, with only rare cells supporting productive
infection. Although the cellular and viral factors that deter-
mine whether EBV infection is latent or productive remain
largely unknown, an EBV immediate-early (IE) gene prod-
uct, BZLF1, has recently been implicated by several labo-
ratories to play an important role in regulating viral latency.
The observation that superinfection with the P3HR1 strain of
EBV disrupts latency has been attributed to the presence of
small defective viral particles which contain the BZLF1
open reading frame (ORF) (9, 15). The BZLF1 gene product
has been demonstrated to encode a transactivating function
which stimulates the expression of at least one EBV early
promoter (7, 16). The BZLF1 IE gene product alone, if
placed in a plasmid under the control of a strong heterolo-
gous promoter, is sufficient to disrupt latency when trans-
fected into EBV-infected lymphoid cells (32).
In this report, we have examined the transregulatory effect
of the BZLF1 gene product on different classes of EBV
promoters. Three EBV promoters active in latent infection
and four promoters active only in productive infection have
been linked to the heterologous chloramphenicol acetyl-
transferase (CAT) gene. We show that whereas the BZLF1
gene product increases the CAT activity of the constructs
directed by the BMLF1 IE promoter and the BMRF1 early
promoter, the CAT activity directed by three latent promot-
ers is decreased. The BZLF1-induced increase in BMLF1
promoter-directed CAT activity is accompanied by a similar
increase in CAT mRNA. We show that the BZLF1 transac-
tivator can function in a variety of cell types (both EBV
positive and negative). In addition, we have constructed
deletion mutants of the BamHI Z fragment and studied the
ability of these mutants to transregulate the EBV-CAT
constructs and disrupt latency in Raji cells.
* Corresponding author.
MATERIALS AND METHODS
Cell lines. All lymphoid cell lines were maintained in RPMI
1640 medium with 10% fetal calf serum. The EBV-positive
cell lines included Raji (a latently infected human Burkitt's
lymphoma line) and B95-8 (a productively infected marmo-
set B-cell line). The EBV-negative cell lines included the
B-cell line Loukes (a human Burkitt's lymphoma line), HeLa
(a cervical epithelial line), and Jurkat (a human T-cell line).
DNA transfection. Plasmid DNA was purified through two
sequential cesium chloride gradients. Transfection into lym-
phoid cell lines was accomplished by using the electropora-
tion technique (33). Cells (107 per condition) were shocked at
1,500 V with the Zapper electroporation unit from the
University of Wisconsin medical electronics shop. Transfec-
tion into HeLa cells was performed by using the calcium
phosphate method (14).
EBV-CAT plasmids. Seven different EBV-CAT plasmids
were constructed by inserting putative EBV promoters into
the BglII site of the vector pCAT3M (25). The pCAT3M
vector contains the bacterial gene encoding CAT and a
simian virus 40 polyadenylation site but no eucaryotic pro-
moter element. The amount of CAT activity produced by
each plasmid is thus a reflection of the activity of the
upstream EBV promoter. Using the primer extension
method (28), we have confirmed that the CAT mRNA in the
pC-CAT construct originates from the expected start site (6)
(data not shown). Primer extension mapping with the pM-
CAT construct is presented in Results. The promoter se-
quences and mRNA start sites in the other EBV constructs
are presumed from the EBV sequence and RNA mapping
studies of previous investigators (3, 5, 8, 20, 26, 30). Table 1
shows the EBV sequence (1) included in each construct.
Construction of the BZLF1 plasmid pEBV-ZIE. Since the
promoter of the BZLF1 gene is quite weak (23), we inserted
the EBV BamHI Z fragment into the BamHI site of the
vector pHD1013 (a gift from Michelle Davis) (22) and named
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TABLE 1. Construction of EBV-CAT plasmids
Plasmid Promoter EBV BamHI Sequences of Genefragment promoter inserta category
pW-CAT EBNA (18, 19, 30) W 44,183-45,084 Latent
pC-CAT EBNA (6) C 10,312-11,336 Latent
pLMP-CAT Latent membrane protein (8, 12, 34) N 169,924-169,476 Latent
pZ-CAT BZLF1 (5) Z 103,625-103,181 IE
pM-CAT BMLF1 (26, 31) M 84,770-84,333 IE
pEA-CAT Early antigen diffuse (BMRF1) (8, 31, 35) M 79,538-79,870 Early
pLATE-CAT gp350/220 (BLLF1) (3) L 92,703-92,160 Late
a The EBV promoter sequences shown were inserted into the BgII site of the vector, pCAT3M (25), upstream of the CAT gene. The EBV inserts (1) were blunt
ended with either the Klenow enzyme or T4 polymerase, ligated into the HinclI site of the PUC-7 vector, and then excised by BamHI digestion for ligation in
pCAT3M.
the resulting construct pEBV-ZIE (Fig. 1). In the pEBV-ZIE
plasmid, the BZLF1 gene is driven by the strong human
cytomegalovirus (CMV) IE promoter. To define the BamHI-
Z sequences required for transregulatory effects, we also
made a series of plasmids that remove different portions of
BamHI-Z from the pEBV-ZIE construct. These deletion
mutants are shown in Fig. 2.
In vitro transcription and translation of BZLF1 deletion
mutants. Since the phD1013 vector was originally derived
from the pGem2 plasmid (Promega) and contains the Sp6
promoter, the Sp6 polymerase enzyme (Promega) was used
to generate sense RNA from plasmids pEBV-ZIE (AHindIll-
Hindlll) and pEBV-ZIE (ASma-Pst) suitable for in vitro
translation. The RNA was translated in rabbit reticulocyte
lysate (Promega) with 60 ,uCi of [35S]methionine (1,134
Ci/mmol) in a 50-,ul volume containing 4 ,ug of RNA at 30°C
for 1 h. Samples were then taken and analyzed by 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
CAT assays. Each EBV-CAT plasmid (5 ,ug) was cotrans-
fected with either the pHD1013 vector or 5 ,ug of the
pEBV-ZIE plasmid or its derivative with 107 lymphoid cells
per condition. Forty-eight hours after transfection, an ex-
tract of the cells was prepared (200 ,ul per condition), and 100
,u1 of the extract was incubated for 1 h at 37°C with
14C-labeled chloramphenicol as previously described (13).
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FIG. 1. Construction of pEBV-ZIE. The EBV BamHI Z frag-
ment, which contains the intact BZLF1 ORF plus portions of two
other ORFs (BZLF2 and BRLF1), was inserted into the BamHI site
of vector pHD1013 (22). The resultant plasmid, pEBV-ZIE, had the
BZLF1 gene driven by the strong human CMV IE promoter.
by thin-layer chromatography followed by autoradiography
and scintillation counting. All CAT assays were repeated
with smaller amounts of extract if the results were not within
the linear range (less than 70% chloramphenicol acetylation).
RNA analysis. Total cellular RNA was prepared 2 days
after transfection by a modification of the Favaloro method
(11, 24). For S1 nuclease quantitation of pM-CAT mRNA, a
complementary RNA probe to pLATE-CAT (Table 1)
mRNA was made by inserting a fragment from pLATE-CAT
containing the EBV promoter plus 250 base pairs (bp) of the
CAT gene into the pGem-2 vector (Promega) next to the Sp6
promoter. Total cellular RNA (35 ,ug) was hybridized over-
night to the 32P-labeled single-stranded RNA probe (6.5 x
104 cpm). The hybrid probe was then digested with S1
nuclease (4), and the S1-protected fragment was electro-
phoresed on a 6% acrylamide gel with 7 M urea. We used the
pLATE-CAT probe for S1 analysis of pM-CAT mRNA in
Raji cells since we found that BZLF1 transfection of Raji
cells results in the production of messages from the endog-
enous EBV genome which hybridize to the pM-CAT probe
and thereby confuse the interpretation of total CAT mRNA
(data not shown). In contrast, the pLATE-CAT probe allows
for quantitative analysis of total CAT mRNA in Raji cells in
the presence and absence of the BZLF1 transactivator but
gives no information regarding the 5' start site.
To determine the actual 5' start site(s) in the pM-CAT
plasmid, we used the primer extension method. A 20-bp
oligonucleotide sequence homologous to the CAT gene in
the region 15 to 34 bp downstream of the ATG codon was
synthesized and labeled with [_y-32P]ATP. Labeled oligonu-
cleotide (105 cpm) was hybridized overnight with 50 ,ug of
RNA at 30°C in a solution containing 80% formamide, 40
mM piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES; pH
6.4), 400 mM NaCl, and 1 mM EDTA. Primer extension was
then performed at 42°C for 90 min with avian myeloblastosis
virus reverse transcriptase as previously described (28).
After RNase digestion, the primer extension products were
electrophoresed on a 6% acrylamide-urea gel.
Assay of EBV productive antigen synthesis. Raji cells were
transfected with 10 ,ug of the pEBV-ZIE plasmid (or a
pEBV-ZIE deletion mutant), and then cells were harvested
by centrifugation at 4 or 6 days after transfection and washed
three times with cold phosphate-buffered saline solution.
Cell smears were prepared on standard painted microscope
slides. After drying, the smears were fixed by cold (-20°C)
acetone for 5 min. Assay of EBV productive antigens was
carried out by the indirect immunofluorescence method with
pooled sera from patients with nasopharyngeal carcinoma
and infectious mononucleosis.
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TABLE 2. Effect of the BZLF1 transactivator in
different cell types
% CAT acetylation without BZLF1
(fold stimulation with BZLF1)
Promoter EBV-positive cells EBV-negative cells
Raji B95-8 Jurkat HeLa
Latent
pW-CAT 2.2 (0.2) 0.3 (1.0) 16.3 (0.1)
pC-CAT 14.1 (0.2) 1.6 (1.6) 11.5 (0.2)
pLMP-CAT 1.6 (0.5) 1.6 (0.9) 3.4 (0.3)
Productive
pZ-CAT 0.2 (1.1) 0.4 (1.8)
pM-CAT 0.3 (46.6) 1.8 (5.8) 1.4 (1.9) 0.2 (3.0)
pEA-CAT 0.4 (8.8) 2.1 (3.3) 0.7 (6.8) 0.2 (30.0)
pLATE-CAT 0.3 (1.6) 0.4 (1.4)
RESULTS
The BZLF1 IE gene product differentially affects latent
versus productive EBV promoters. To examine the effect of
the BZLF1 IE gene product on different classes of EBV
promoters, 5 ,ug of each EBV-CAT plasmid was cotrans-
fected with either 5 ,ug of the pHD1013 vector or 5 ,ug of the
pEBV-ZIE vector. Table 2 shows the results of these exper-
iments. In the latently infected B-cell line, Raji, the activity
of the two CAT vectors containing the BMLF1 (pM-CAT)
and BMRF1 (pEA-CAT) productive promoters, which are
normally active only in productive infection, was stimulated
by cotransfection with the pEBV-ZIE plasmid. On the other
hand, the activity of the three promoters which are actively
expressed during latent EBV infection was consistently
down regulated by cotransfection with pEBV-ZIE. This
decrease in latent promoter activity could not be accounted
for by a promoter competition effect, since the pHD1013
control vector also contains the human CMV IE promoter.
Furthermore, this down-regulating effect on latent promot-
ers was observed with multiple plasmid preparations of
pEBV-ZIE. The activity of two other CAT constructs,
pRSV-CAT and pHIV-CAT, which contain the Rous sar-
cotna virus (22) and human immunodeficiency virus promot-






The ability of BZLF1 to function as a transregulator was
studied in several different cell lines. The BZLF1 gene
product increased the activity of the pM-CAT and pEA-CAT
constructs in both latently (Raji) and productively (B95-8)
infected B-cell lines, as well as in the epithelial line, HeLa,
and the T-cell line, Jurkat. The latent promoters were down
regulated by BZLF1 in Raji and Jurkat cells but not in B95-8
cells (productively infected B cells). In HeLa cells, the
constitutive activity of these promoters is too low to observe
any negative effect. The BZLF1 IE promoter (pZ-CAT) and
the gp350/220 late promoter (pLATE-CAT) were not signif-
icantly affected by cotransfection with the BZLF1 gene
product in any cell type.
In contrast to a report by other investigators (7), these
data show that the BZLF1 transactivator clearly functions in
EBV-negative as well as EBV-positive cell types. However,
we did find that the BZLF1-induced increase in pM-CAT
activity was consistently much greater in EBV-positive than
in EBV-negative cell lines. This much greater effect on
pM-CAT expression in EBV-positive cells suggests that
another EBV gene product(s) may contribute to transactiva-
tion of the BMLF1 promoter by BZLF1. The BMRF1
promoter, on the other hand, is stimulated by BZLF1 at least
as well in EBV-negative cells as in EBV-positive cells. The
different effects ofBZLF1 in the latently versus productively
infected B-cell lines may be due to the constitutive expres-
sion of BZLF1 in the productive cell line, in addition to the
expression of other EBV-encoded transactivating proteins
such as the recently described BamHI-R transactivator,
BRLF1 (16).
The BZLF1 transactivator increases the level of mRNA
from susceptible promoters. We next determined whether the
positive stimulatory effect of the BZLF1 transactivator on
the CAT activity of the pM-CAT construct is accompanied
by a similar increase in CAT mRNA. We recently found that
the EBV BMLF1 transactivator may function at least partly
at a posttranscriptional level since it increases CAT activity
but has little effect on CAT mRNA (22) in cotransfection
experiments. In contrast, Si nuclease analysis of the BZLF1
effect on CAT mRNA levels indicates that this transactivator
significantly increases the steady-state level of CAT mRNA
from susceptible promoters.
In the experiment shown in Fig. 3, the pM-CAT construct
(5 ,ug) was cotransfected into Raji cells with either 5 ,ug of
EBV Bam HI Z Fragment













FIG. 2. Construction of pEBV-ZIE deletion mutants. To construct each deletion mutant, pEBV-ZIE was cut with the restriction enzymes
shown, blunt ended with T4 polymerase (except for the HindlIl-HindlIl mutant which was not blunt ended), and then religated. The hatched
area shows the deleted portion ofBamHI-Z. EBV-ZIE (AMstII-BamHI) contains the intact 200-amino-acid BZLF1 ORF but deletes a portion
of the BRLF1 ORF. pEBV-ZIE (AHindIII-HindIII) has an in-frame deletion which removes amino acids 24 to 86 from BZLF1. pEBV-ZIE
(ASma-Pst) removes amino acids 132 to 200 from BZLF1. The above description of the pEBV-ZIE deletions assumes no splicing of the
BZLF1 mRNA. However, a potential splice in the BZLF1 message creates a 245-amino-acid ORF which has the same 167 amino-terminal
amino acids but an altered carboxy-terminal end (5, 21).
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FIG. 3. Effect of the BZLF1 transactivator on steady-state CAT
mRNA with Si nuclease analysis. The pM-CAT (5 ,g) plasmid was
cotransfected into Raji cells with either 5 jig of the pHD1013 vector,
pEBV-MIE (22), which encodes the EBV BMLF1 transactivator, or
pEBV-ZIE, which encodes the BZLF1 transactivator. At the level
of CAT activity, cotransfection with pEBV-MIE and pEBV-ZIE
increased pM-CAT activity 25-fold and 20-fold, respectively. After
hybridization with an Sp6 polymerase-generated antisense pLATE-
CAT probe, the expected size of the Si nuclease-protected RNA
fragment is 270 bp (the length of homology between the pLATE-
CAT probe and the pM-CAT plasmid). Whereas the pEBV-MIE
transactivator has little effect on pM-CAT mRNA levels, the pEBV-
ZIE transactivator clearly increases steady-state CAT mRNA.
pHD1013, 5 pLg of pEBV-MIE (22) (which has the BMLF1
transactivator under the control of the CMV IE promoter),
or 5 ,ug of pEBV-ZIE (BZLF1 transactivator controlled by
the CMV IE promoter). In this experiment, cotransfection
with pEBV-MIE increased the CAT activity of pM-CAT
25-fold, and cotransfection with the pEBV-ZIE plasmid
increased CAT activity 20-fold. However, at the level of
steady-state mRNA, the EBV-MIE transactivator had no
effect, whereas EBV-ZIE increased mRNA 16-fold (as mea-
sured by laser densitometry). The effect of the BZLF1
transactivator on mRNA levels was analyzed by S1 nuclease
analysis in three separate experiments, and in each case the
increase in CAT mRNA produced was comparable to the
increase in CAT activity.
We also used the primer extension method to determine
whether the presence of the BZLF1 transactivator can alter
the 5' start site in the BMLF1 promoter region. These results
are shown in Fig. 4. Although the BMLF1 mRNA start site
has not been precisely mapped, a potential TATA box
element has been noted upstream of the ATG codon (1). Our
...
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FIG. 4. Primer extension analysis of pM-CAT RNA. The pM-
CAT plasmid was cotransfected into Raji cells with either 5 jig of the
pHD1013 vector (lane B) or 5 ,ug of the BZLF1 transactivating
plasmid, pEBV-ZIE (lane C). RNA (50 ,ug) from untransfected Raji
cells (lane A) or the pM-CAT transfected cells was hybridized
overnight with a 32P-labeled oligonucleotide primer homologous to
CAT gene sequences 15 to 34 bp downstream of the ATG codon.
Primer extension was then performed with reverse transcriptase at
42°C for 90 min (28). The expected size of the primer extension
product if the BMLF1 promoter TATA box is used is approximately
100 bp. A band of the expected size is detected (lower arrow) in
addition to a larger band mapping to the region approximately 20 bp
upstream of the TATA box (upper arrow). The BZLF1 transactiva-
tor does not affect use of the mRNA start sites.
pM-CAT construct contains this TATA box element plus an
additional 25 bp of downstream sequences. Preliminary
primer extension analysis has revealed the expected start
site downstream of the TATA box (the smaller band in Fig.
4), plus an additional unexpected band that maps to a region
approximately 20 bp upstream of the TATA box (assuming
no splicing occurs). This upstream start site was seen in two
separate experiments and appeared to be a major start site in
our plasmid. However, since our plasmid may not include
the endogenous cap site downstream of the TATA box, this
may favor use of the upstream start site. In any event, the
BZLF1 transactivator was not found to promote the use of
any additional mRNA start site.
Analysis of BamHI-Z sequences required for transactiva-
tion. Because the pEBV-ZIE construct contains the entire
BamHI Z fragment, including not only the intact BZLF1
ORF but also two other partial ORFs, we made several
deletion mutants of the pEBV-ZIE plasmid to ascertain
whether it was in fact the BZLF1 gene product that was
responsible for the observed transactivating effects (Fig. 2).
To assure that the pEBV-ZIE deletion plasmids which alter
the BZLF1 ORF can make a stable protein product of the
predicted size, we used Sp6 polymerase to synthesize RNA
J. VIROL.
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FIG. 5. In vitro translation of pEBV-ZIE deletion mutants. The
pEBV-ZIE plasmid (lane C), the pEBV-ZIE (AHindIII-HindIII)
mutant (lane B), and the pEBV-ZIE (ASma-Pst) mutant (lane A)
were transcribed in vitro with Sp6 polymerase and then translated in
a rabbit reticulocyte lysate system in the presence of [35S]me-
thionine. The pEBV-ZIE plasmid, as expected, produces a protein
of approximately 34 kilodaltons. The two deletion plasmids produce
smaller protein products of the expected size. Numbers on the right
give molecular mass in kilodaltons.
in vitro followed by in vitro translation of the RNA. The
resultant protein products were labeled with [35S]methionine
and run on a sodium dodecyl sulfate-polyacrylamide gel
(Fig. 5). With this technique, the parent pEBV-ZIE con-
struct was found to make the expected protein product of
approximately 34 kilodaltons (21). The pEBV-ZIE
(AHindlll-Hindlll) plasmid, which removes amino acids 24
to 86, was shown to produce a protein product of approxi-
mately 24 kilodaltons, and pEBV-ZIE (ASma-Pst), which
has amino acids 120 to 200 removed, produces a protein
product of approximately 23 kilodaltons.
We next examined the ability of these pEBV-ZIE deletion
constructs to transactivate the different EBV promoters
(Table 3). The plasmid pEBV-ZIE (AMst-BamHI), which
removes most of the BRLF1 ORF but leaves the BZLF1
ORF intact, produces better transactivation of the pM-CAT
construct than the parent plasmid, pEBV-ZIE, and also
appears to function more efficiently as a down regulator
of pC-CAT activity. The plasmid pEBV-ZIE (AHindIII-
HindIII) contains an in-frame deletion which removes a large
portion of the amino-terminal half of the 200-amino-acid
BZLF1 ORF (amino acids 24 to 86 removed). In spite of this
deletion, this plasmid still functions as a positive transacti-
vator of pM-CAT, although less effectively than the parent,
pEBV-ZIE (Table 3). On the other hand, the pC-CAT
plasmid is consistently not down regulated by pEBV-ZIE
(AHindIll-HindIll). The plasmid pEBV-ZIE (ASma-Pst),
which has the carboxy-terminal half (amino acids 120 to 200)
of the BZLF1 ORF deleted, no longer functions as either a
positive or negative transregulator. Thus, amino acids 24 to
86 in BZLF1 are not essential for the positive transactivating
effects on the BMLF1 promoter, but may be required for
negative regulation. The carboxy-terminal half of BZLF1
appears to be essential for both positive and negative regu-
lation.
Disruption of viral latency by pEBV-ZIE deletion plasmids.
TABLE 3. Effect of pEBV-ZIE deletions on transactivation
Fold stimulation of
Plasmid CAT activity
Expt 1 Expt 2
pM-CAT'
+pEBV-ZIE 17.0 91.1
+pEBV-ZIE (AMst-BamHfl) 29.7 104.4
+pEBV-ZIE (AHindlIl-HindlIl) 5.0 14.3
+pEBV-ZIE (ASma-Pst) 1.0 1.9
pC-CATb
+pEBV-ZIE 0.4 0.4
+pEBV-ZIE (AMst-BamHl) 0.2 0.2
+pEBV-ZIE (AHindIll-HindIll) 1.9 0.9
+pEBV-ZIE (ASma-Pst) 1.2 1.2
aConstitutive activity was measured as percent acetylation of chloram-
phenicol without pEBV-ZIE and was 0.3 and 0.4% for experiments 1 and 2,
respectively.
b Constitutive activity was measured as percent acetylation of chloram-
phenicol without pEBV-ZIE and was 12.7 and 14.2% for experiments 1 and 2,
respectively.
We also compared the ability of the pEBV-ZIE deletion
mutants to disrupt viral latency when transfected into the
Raji cell line. The pEBV-ZIE and pEBV-ZIE (AMst-BamHI)
plasmids (each of which contains the intact BZLF1 ORF)
both clearly induce the expression of productive viral anti-
gens when transfected into the normally tightly latent Raji
cells (Fig. 6). However, we could not detect disruption of
latency with the two plasmids containing deletions in either
the amino-terminal portion [pEBV-ZIE (AHindIll-HindI11)]
or carboxy-terminal portion of BZLF1 [pEBV-ZIE (ASma-
Pst)]. Thus, although the pEBV-ZIE (AHindIII-HindIII)
plasmid retains the capacity for positive but not negative
transactivation of the BMLF1 promoter, it has lost the
ability to disrupt viral latency, suggesting that down regula-
tion of latent promoters may contribute to the disruption of
latency. Alternatively, the CAT assay may simply be a more
sensitive method of detecting transregulatory function than
is detection of antigens by serology.
DISCUSSION
Infection of lymphocytes with EBV results in immortal-
ization and transformation of B cells in vitro and is associ-
ated with polyclonal lymphoproliferation and Burkitt's lym-
phoma in the human host (10). The transregulatory functions
of the EBV BZLF1 gene product are likely to play an
important role in viral regulation and cellular transformation.
In this paper, we have examined the effect of the BZLF1
gene product on different classes ofEBV promoters. We find
that the BZLF1 gene product positively transactivates two
early EBV promoters (BMLF1 and BMRF1) but down
regulates the expression of three latent EBV promoters (the
BamHI-W and BamHI-C Epstein-Barr nuclear antigen
[EBNA] promoters and the latent membrane protein pro-
moter). Both of these BZLF1 effects occur in EBV-negative
as well as EBV-positive cells and therefore do not require
the presence of additional EBV gene products. The increase
in pM-CAT activity produced by the BZLF1 transactivator
is accompanied by a correspondingly similar increase in
CAT mRNA. In addition, we show that a portion of the
amino-terminal half of the BZLF1 ORF, although not essen-
tial for up regulation of the BMLF1 promoter, may be
required for down regulation of the latent promoters and
disruption of viral latency.
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FIG. 6. Disruption of viral latency by pEBV-ZIE deletion plasmids. The latently infected Raji cells were transfected with 5 ,ug ofpM-CAT
and 5 ,ug of pHD1013 vector DNA (A), pEBV-ZIE (B), pEBV-ZIE (A&Mst-BamHI) (C), pEBV-ZIE (AHindIII-HindIII) (D), or pEBV-ZIE
(/Sma-Pst) (E). Two days after transfection, CAT assay analysis in a sample of the cells showed that, as expected, the cultures cotransfected
with the pEBV-ZIE, pEBV-ZIE (AMst-BamHI), and pEBV-ZIE (AHindIII-HindIII) plasmids all had increased pM-CAT activity compared
with the pHD1013 control condition. At 4 days after transfection, the cells from each condition were examined by indirect immunofluores-
cence (with pooled patient sera) for the expression of EBV productive antigens. Representative fields are shown for each condition. Only the
cells transfected with pEBV-ZIE or pEBV-ZIE (AMst-BamHI) had detectable EBV productive antigens. The results were identical in a repeat
experiment examined by immunofluorescence at 6 days after transfection.
The precise mechanism by which the BZLF1 gene product
disrupts latency is still unproven, but may well be related to
its transregulatory effects on the promoters of key EBV
genes. Our data demonstrate that the BZLF1 transactivator
increases the activity of the promoters of two EBV regula-
tory genes, BMLF1 and BMRF1. Since both the BMLF1
and BMRF1 gene products also encode known transactivat-
ing functions (7, 26, 29, 35), the ability of BZLF1 to disrupt
latency could well be mediated through its stimulation of the
BMLF1 or BMRF1 promoters, or both. However, although
we find that the BZLF1 gene product alone (under the
control of the CMV IE promoter) is sufficient to disrupt
latency in Raji cells, we do not find that either the BMLF1 or
BMRF1 gene products (when likewise placed under the
control of the CMV IE promoter) can disrupt latency in Raji
cells (S. Kenney, unpublished data). The inability of high
expression of either the BMLF1 or BMRF1 transactivator
alone to disrupt latency suggests that the combined expres-
sion of both of these transactivators, and perhaps the
BamHI-R transactivator (16) as well, may be required for
disruption of latency.
Alternatively, the ability of the BZLF1 to down regulate
expression of latent EBV genes may also contribute to the
disruption of latency. We find that the deletion mutant
J. VIROL.
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pEBV-ZIE (AHindlll-HindIII), which retains the ability to
up regulate the BMLF1 productive promoter but has lost the
ability to down regulate the BamHI-C EBNA promoter, no
longer disrupts viral latency. As previously suggested by
Baichwal and Sugden (2), the EBNA 1 transcript could
theoretically act as an antisense RNA to the BZLF1 tran-
script, thereby reducing translation of BZLF1. A reduction
in EBNA transcription may thus be required if adequate
synthesis of the BZLF1 gene product is to occur for disrup-
tion of latency.
Countryman et al. (9) have previously analyzed the se-
quences from defective EBV virions required for disruption
of latency. These investigators found that a particular DNA
clone, WZhet, which contains the BamHI Z fragment linked
to a portion of the BamHI W fragment, is capable of
disrupting viral latency. Deletion analysis of the WZhet
fragment showed that it is the BZLF1 ORF that is required
for disruption of latency, whereas the BamHI-W sequences
are dispensable. These investigators reported that a site-
directed mutation in the upstream HindIll site of BZLF1
destroyed the ability of BZLF1 to disrupt latency. However,
in contrast to our own HindlIl-HindIII deletion, this muta-
tion disrupted the BZLF1 ORF.
The BZLF1-induced increase in pM-CAT mRNA as well
as CAT activity suggests that the increase in CAT activity
may be mediated by a transcriptional mechanism. Absolute
proof of a transcriptional mechanism would require the use
of nuclear run-on studies, which we have not yet performed.
In comparing the sequences of the two promoters stimulated
by BZLF1 (the BMLF1 and BMRF1 promoters), we have
been unable to identify any common motif. Likewise, we
have not identified any sequence similarity in the three latent
promoters down regulated by BZLF1. At this point, it is
unknown whether the BZLF1 transactivator exerts its effect
directly by binding to promoter sequences or indirectly
through an effect on cellular proteins. However, it is clear
that the BZLF1 gene product does not produce indiscrimi-
nant transactivation of all EBV productive promoters, since
we find that only two of the four productive EBV promoters
tested are up regulated by BZLF1.
It will now be of particular interest to study the regulation
of the BZLF1 gene product itself. To maintain a latent
infection of lymphoid cells, the expression of BZLF1 must
be tightly controlled, since overexpression of the gene leads
irreversibly to productive infection and death of the host
cell, which is perhaps a disadvantage to the virus. We have
previously shown that the presumed BZLF1 promoter re-
gion functions very poorly in latently infected B-cell lines,
although its activity can be increased by 12-0-tetra-de-
canoyl-phorbol-13-acetate (23), which also disrupts viral
latency (27). A major control mechanism in EBV may be
directed at preventing the expression of BZLF1 in B cells (in
which viral infection is largely latent), while allowing the
expression of BZLF1 within the epithelial cells that are
permissive for EBV replication.
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